Sulforaphane reduces lipopolysaccharide-induced inflammation and enhances myogenic differentiation of mouse embryonic myoblasts via the toll-like receptor 4 and NLRP3 pathways
Advances in Clinical and Experimental Medicine · 2022
DOI: 10.17219/acem/155342 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advances in Clinical and Experimental Medicine, 2022. Verfasst von Manfeng Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Geriatrics, Second Affiliated Hospital of Harbin Medical University, China. Hauptthemen laut MEDLINE: Sarcopenia, Sepsis. Die Arbeit wurde bisher 7-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Geriatrics, Second Affiliated Hospital of Harbin Medical University, China.
- Department of Neurosurgery, The First Hospital of Jilin University, Changchun, China.
Zitieren
APA
Wang, M., Liu, M., Xu, W., Teng, Z., Wu, X., Gan, L., & Zhang, Y. (2022). Sulforaphane reduces lipopolysaccharide-induced inflammation and enhances myogenic differentiation of mouse embryonic myoblasts via the toll-like receptor 4 and NLRP3 pathways. Advances in Clinical and Experimental Medicine. https://doi.org/10.17219/acem/155342
Vancouver
Wang M, Liu M, Xu W, Teng Z, Wu X, Gan L, et al. Sulforaphane reduces lipopolysaccharide-induced inflammation and enhances myogenic differentiation of mouse embryonic myoblasts via the toll-like receptor 4 and NLRP3 pathways. Advances in Clinical and Experimental Medicine. 2022. doi:10.17219/acem/155342
BibTeX
@article{Wang2022,
author = {Wang, Manfeng and Liu, Meiling and Xu, Wanzhen and Teng, Zongyan and Wu, Xiaowei and Gan, Lu and Zhang, Yina},
title = {Sulforaphane reduces lipopolysaccharide-induced inflammation and enhances myogenic differentiation of mouse embryonic myoblasts via the toll-like receptor 4 and NLRP3 pathways},
journal = {Advances in Clinical and Experimental Medicine},
year = {2022},
doi = {10.17219/acem/155342}
}
EUVIMED